Literature DB >> 34872342

Comparison of Two Automated Computed Tomography Perfusion Applications to Predict the Final Infarct Volume After Thrombolysis in Cerebral Infarction 3 Recanalization.

Bernd Kallmünzer1, Arnd Doerfler2, Iris Muehlen2, Maximilian Sprügel1, Philip Hoelter2, Stefan Hock2, Michael Knott2, Hagen B Huttner1, Stefan Schwab1.   

Abstract

BACKGROUND: Several automated computed tomography perfusion software applications have been developed to provide support in the definition of ischemic core and penumbra in acute ischemic stroke. However, the degree of interchangeability between software packages is not yet clear. Our study aimed to evaluate 2 commonly used automated perfusion software applications (Syngo.via and RAPID) for the indication of ischemic core with respect to the follow-up infarct volume (FIV) after successful recanalization and with consideration of the clinical impact.
METHODS: Retrospectively, 154 patients with large vessel occlusion of the middle cerebral artery or the internal carotid artery, who underwent endovascular therapy with a consequent Thrombolysis in Cerebral Infarction 3 result within 2 hours after computed tomography perfusion, were included. Computed tomography perfusion core volumes were assessed with both software applications with different thresholds for relative cerebral blood flow (rCBF). The results were compared with the FIV on computed tomography within 24 to 36 hours after recanalization. Bland-Altman was applied to display the levels of agreement and to evaluate systematic differences.
RESULTS: Highest correlation between ischemic core volume and FIV without significant differences was found at a threshold of rCBF<38% for the RAPID software (r=0.89, P<0.001) and rCBF<25% for the Syngo software (r=0.87, P<0.001). Bland-Altman analysis revealed best agreement in these settings. In the vendor default settings (rCBF<30% for RAPID and rCBF<20% for Syngo) correlation between ischemic core volume and FIV was also high (RAPID: r=0.88, Syngo: r=0.86, P<0.001), but mean differences were significant (P<0.001). The risk of critical overestimation of the FIV was higher with rCBF<38% (RAPID) and rCBF<25% (Syngo) than in the default settings.
CONCLUSIONS: By adjusting the rCBF thresholds, comparable results with reliable information on the FIV after complete recanalization can be obtained both with the RAPID and Syngo software. Keeping the software specific default settings means being more inclusive in patient selection, but forgo the highest possible accuracy in the estimation of the FIV.

Entities:  

Keywords:  brain ischemia; carotid arteries; cerebral stroke; middle cerebral artery; perfusion imaging; stroke, acute

Mesh:

Year:  2021        PMID: 34872342     DOI: 10.1161/STROKEAHA.121.035626

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  3 in total

1.  RAPID CT Perfusion-Based Relative CBF Identifies Good Collateral Status Better Than Hypoperfusion Intensity Ratio, CBV-Index, and Time-to-Maximum in Anterior Circulation Stroke.

Authors:  A Potreck; E Scheidecker; C S Weyland; U Neuberger; C Herweh; M A Möhlenbruch; M Chen; S Nagel; M Bendszus; F Seker
Journal:  AJNR Am J Neuroradiol       Date:  2022-06-09       Impact factor: 4.966

2.  Prognostic Accuracy of CTP Summary Maps in Patients with Large Vessel Occlusive Stroke and Poor Revascularization after Mechanical Thrombectomy-Comparison of Three Automated Perfusion Software Applications.

Authors:  Iris Muehlen; Matthias Borutta; Gabriela Siedler; Tobias Engelhorn; Stefan Hock; Michael Knott; Philip Hoelter; Bastian Volbers; Stefan Schwab; Arnd Doerfler
Journal:  Tomography       Date:  2022-05-17

3.  CT perfusion-based delta-radiomics models to identify collateral vessel formation after revascularization in patients with moyamoya disease.

Authors:  Jizhen Li; Yan Zhang; Di Yin; Hui Shang; Kejian Li; Tianyu Jiao; Caiyun Fang; Yi Cui; Ming Liu; Jun Pan; Qingshi Zeng
Journal:  Front Neurosci       Date:  2022-08-11       Impact factor: 5.152

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.